Early Side Effects after Administration of the 1st Dose of Oxford-AstraZeneca Vaccine 1 2 Short title: Side Effects AstraZeneca 3

- Pramod Singh^{1*}, Abdul Rafae Faisal¹, M. Hassaan Shah², Ahmad Saeed¹, Hadia Younas³, 4
- Usamah Saeed Butt⁴, Sudip Pudasaini⁵, Abdul Rafay Pasha⁶, Umair Rehman¹ 5
- 6
- 7 ¹Department of Surgery, Punjab Medical College, Faisalabad, Punjab, Pakistan
- ² Department of Medicine, Oazi Hussain Ahmad Medical Complex, Nowshera, KPK, 8
- 9 Pakistan
- 10 ³ Department of Medicine, Services Institute of Medical Sciences, Lahore, Punjab, Pakistan
- 11 ⁴Department of Medicine, King Edward Medical University, Lahore, Pakistan
- 12 ⁵ Department of Medicine, Nepal Medical College, Kathmandu, Nepal
- ⁶ Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan 13

14

- 15 *Corresponding author
- E-mail: singhutd66@gmail.com 16
- 17

2

18 Abstract

Vaccines have played a central role in minimizing new infections, the rate of hospitalizations, 19 20 and the overall burden on the health sector. Fear of side-effects is the biggest and commonest reason for avoiding getting vaccinated. It is, therefore, essential to maintain the clarity and 21 22 consistency of message, to support and encourage people to get vaccinated. This study aims to contribute in that regard, by registering and quantifying the early side-effects of the 23 Oxford-AstraZeneca COVID-19 vaccine in Pakistan. This study employs a non-random 24 25 cross-sectional design. Data collected from 477 participants using a structured questionnaire 26 was used to investigate the relationship between socio-demographic characteristics and side effect profiles of the participants. Binomial Logistic Regression was used to analyze the data. 27 Odds Ratio (OR) gives the likelihood of having a side effect versus the reference group. 28 29 Significance level (α) for the probability value (p-value) is set at 0.05. Fever (30.19%) was 30 the most commonly experienced side effect, followed closely by fatigue (22.01%). 71.11% of those with fever experienced low grade fever (99-100F) while 62.69% of body aches 31 32 experienced were moderate in intensity (Grades 4-6). In general, younger people are significantly more likely (p=0.023) to experience side effects (OR⁻¹ = 1.023: interpreted as 33 1.023 times increase per unit decrease in age). Similarly, they are more likely (p=0.029) to 34 35 have a headache ($OR^{-1} = 1.039$). Also, they are more likely (p = 0.007) to have a body ache 36 (OR⁻¹ =1.038). The Oxford-AstraZeneca COVID-19 vaccine side-effects seem to be more

- prevalent among younger age groups, which points to increased vaccine safety among older 37
- 38 individuals that are usually more susceptible to severe COVID-19 infection. In addition, we
- 39 found a substantially reduced number of side-effects, as compared to the clinical trials, which
- is an encouraging indicator for vaccine safety. 40

Introduction 41

Since the COVID-19 pandemic started in early 2020, the world has undergone drastic and 42

- disruptive changes. The wave upon wave of new infections, constantly having to follow 43
- restrictions and fears of the deadly disease has left enduring scars on the public psyche [1]. 44
- 45 Not only this, but the pandemic has led to trillions of dollars of loss to the world economy
- 46 [2].

47 For this pandemic to end, vaccines have played a central role in minimizing new infections,

- the rate of hospitalizations and the overall burden on the health sector. A large percentage of 48
- 49 the world's population has to be vaccinated in a short period of time to achieve the herd
- 50 immunity required to stop the propagation of the Coronavirus [3].
- 51 These vaccines have varying mechanisms of actions. Some are mRNA vaccines, like Pfizer-
- 52 BioNtech and Moderna COVID-19 vaccines, while others, like the Janssen shot, are non-
- 53 replicating viral vector vaccines. Moreover, the Oxford-AstraZeneca vaccine is an
- 54 Adenovirus vaccine and Sputnik V is a recombinant Adenovirus vaccine. Many others are
- 55 inactivated vaccines like Sinopharm and Sinovac vaccines [4, 5].

- 3
- Side effects have been the cause of concern for many and have led to delay in getting 56
- vaccinated. This delay in vaccine acceptance, vaccine hesitancy, is turning out to be an 57
- emerging public health problem. [6, 7] According to multiple studies, fear of side-effects is 58
- the biggest and commonest reason for avoiding getting vaccinated [8, 9]. It is, therefore, 59
- 60 essential to maintain the clarity and consistency of message, to support and encourage people to get vaccinated. 61
- Pakistan started its vaccination campaign with Sinopharm, Sinovac, CanSino and Sputnik V 62
- [10]. This effort received public backlash from some quarters. Keeping in mind the dire need 63
- 64 of the rapid vaccination of the masses, it is important to maintain the public's trust, which can
- only be based on adequate statistical data regarding the safety of the vaccine. This study aims 65
- to contribute in that regard, by registering and quantifying the early side-effects of the 66
- Oxford-AstraZeneca COVID-19 vaccine in Pakistan. 67

68 **Materials and Methods**

The study was conducted in July 2021. All individuals presenting at the vaccination site that 69

- were within government-approved age groups (at the time of data collection, 40 years and 70
- 71 above) were considered for the study.
- Individuals with acute febrile illness (last 72 hours), history of COVID-19 infection (positive 72
- PCR), prior COVID-19 vaccination., history of foreign travel during the past 3 months, 73
- 74 receiving any investigational drug for COVID-19 (including for prophylaxis) during the last
- 30 days, receiving systemic immunoglobulins, monoclonal antibodies and/or convalescent 75
- 76 serum during the past 4 months, significant or severe co-morbidities [Diabetes mellitus,
- hypertension, chronic pulmonary disease, asthma, active smoker or vapers (during the past 77
- 78 vear). BMI> 30 Kg/m2, history of anaphylaxis or urticaria or other adverse effects related to
- 79 vaccine or its components, severe or uncontrolled heart disease, cancer and any other severe
- disease, bleeding disorder, known or suspected immunodeficient status [HIV, 80
- immunosuppressive drugs (cytotoxins and steroids) and asplenia], blood donation during the 81
- 82 last 28 days, known or suspected alcohol or drug dependency, pregnancy or breastfeeding,
- 83 participating in any research study during the past 28 days were excluded from the study.
- This study employs a non-random cross-sectional design. Data collected from 477 84
- participants using a structured questionnaire was used to investigate the relationship between 85
- 86 socio-demographic characteristics and side effect profiles of the participants. Only those
- participants that met the inclusion criteria for this study were selected for follow up. The 87
- 88 participants were followed on Day 1, 3, and 7 to gather data regarding side-effects. Data was
- analyzed descriptively and inferentially by IBM SPSS 24. Binomial Logistic Regression was 89
- 90 used to analyze the data. For missing data regarding Educational status, data was imputed
- 91 using mice package in R. Odds Ratio (OR) gives the likelihood of having a side effect versus
- the reference group. Significance level (α) for the probability value (p-value) is set at 0.05. 92
- 93 Results

- 4
- 94 477 individuals participated in this study. Of them, 51.15% of the respondents belonged to
- the 40-49 age group, followed by the 50-59 age group which had 31.24% participants. 95
- 44.89% had primary education or below. A vast majority, 72.54%, were male. Fever 96 (30.19%) was the most commonly experienced side effect. followed closely by fatigue 97
- (22.01%). 71.11% of those with fever experienced low grade fever (99-100F) while 62.69% 98
- 99 of body aches experienced were moderate in intensity (Grades 4-6) [Table 1]. In general,
- younger people are significantly more likely (p=0.023) to experience side effects ($OR^{-1} =$ 100
- 1.023: interpreted as 1.023 times increase per unit decrease in age). Similarly, they are more 101
- likely (p=0.029) to have a headache (OR⁻¹=1.039). Also, they are more likely (p=0.007) to 102
- have a body ache ($OR^{-1} = 1.038$). In general, higher educational status reported a higher 103
- frequency of side effects (p < 0.05) [Table 2]. 104

105	Table 1.	Frequency	of side	effects.
-----	----------	-----------	---------	----------

Side effects	Frequency	Percentage
Headache	21	4.4
Flu-like illness	0	0
Pain, swelling, rash, bleeding or redness at the site of		
injection	56	11.74
Fatigue	18	3.77
Anaphylaxis reaction	1	0.21
Fever	144	30.19
Low Grade [99F -100F]	64	71.11
Moderate [100.1F -103 F]	21	23.33
High grade [103.1 F-106 F]	5	5.56
Undocumented	54	-
Dadwasha	105	22.01
Body ache Grade (1-3)	8	11.94
Grade (4-6)	42	62.69
Grade (7-9)	17	25.37
Undocumented	38	-

Table 2. Binary Logistic Regression. 106

		Reference	Log		Ordinal
Side effect	Variables	group	odds	p-value	Regression(OR)
Headache	Age		-0.077	0.029*	0.926
	Male	Female	0.521	0.339	1.685
		Primary or			
	Matric or Below	below	0.269	0.658	1.31
	Intermediate or	Primary or			
	below	below	-16.268	0.989	0
	Bachelors and	Primary or			
	above	below	1.378	0.015*	3.968
	Urban	Rural	-0.897	0.210	0.408
Injection site					
reaction	Age		-0.017	0.304	0.983

5

	Male	Female	0.081	0.803	1.085
	141010	Primary or	0.001	0.005	1.005
	Matric or Below	below	0.083	0.829	1.085
	Intermediate or	Primary or	0.005	0.02)	1.000
	below	below	0.526	0.21	1.693
	Bachelors and	Primary or			
	above	below	0.459	0.272	1.583
	Urban	Rural	-0.440	0.327	0.644
Fatigue	Age		0.014	0.583	1.014
1 411940	Male	Female	-0.845	0.091	0.43
	White	Primary or	0.015	0.071	0.15
	Matric or Below	below	1.422	0.030*	4.149
	Intermediate or	Primary or		0.000	
	below	below	-0.076	0.947	0.927
	Bachelors and	Primary or			
	above	below	1.620	0.022*	5.058
	Urban	Rural	-0.070	0.932	1.81x10 ⁸
Anaphylaxis	Age		-0.085	0.587	0.918
	Male	Female	-19.4	0.999	0
		Primary or			
	Matric or below	below	-18.8	0.999	0
	Intermediate or	Primary or			
	below	below	-19.1	0.999	0
	Bachelors and	Primary or			
	above	below	-19.8	0.999	0
	Urban	Rural	19	0.999	1.81x10 ⁸
Fever	Age		-0.015	0.182	0.984
	Male	Female	0.180	0.442	1.198
		Primary or			
	Matric or Below	below	-0.410	0.149	0.663
	Intermediate or	Primary or			
	below	below	0.480	0.107	1.616
	Bachelors and	Primary or			
	above	below	0.719	0.0128*	2.053
	Urban	Rural	0.705	0.074	2.025
Body ache	Age		-0.037	0.007*	0.963
	Male	Female	-0.194	0.433	0.823
		Primary or			
	Matric or Below	below	0.394	0.168	1.483
	Intermediate or	Primary or			
	below	below		0.966	1.015
	Bachelors and	Primary or			
	above	below	0.571	0.075	1.771
	Urban	Rural	-0.287	0.430	0.75
Any side effect	Age		-0.023	0.023*	0.977
	Male	Female	0.189	0.367	1.209
	whate		0.107	0.001	
	Wate	Primary or	0.109	0.007	

6

Bachelors and Primary or	Intermediate or below	Primary or below	0.389	0.176	1.477
above below 0.271 0.185 1.	Bachelors and	Primary or			
above below 0.3/1 0.183 1.4	above	below	0.371	0.185	1.451
Urban Rural -0.100 0.733 0.9	Urban	Rural	-0.100	0.733	0.904

107 *probability value (p-value) <0.05

108 Discussion

In this study, we attempted to confirm the presence and measure the frequency of occurrence 109

110 of AstraZeneca vaccine's early adverse effects in Pakistan. These included headache, body

111 aches, fatigue, fever, injection site reaction, flu-like illness and anaphylaxis. Except for the

112 flu-like illness and anaphylaxis, for all COVID-19 vaccines, these early side effects are,

generally speaking, the commonest early COVID-19 vaccine side effects [11], 49.47% of the 113

114 respondents in our study had, at least, one of these symptoms.

The side-effects were categorized as local and systemic. Local effects refer to injection site 115

reactions which include pain, swelling, rash, redness or bleeding at the site of vaccination. 116

117 They were present only in 11.74% of the study population which is in marked contrast to

118 phase 2/3 trials, that showed a considerably higher occurrence across all age groups (88% in

119 the 18–55 years group, 73% in the 56–69 years group, and 61% in 70 years and older group),

120 and phase 1/2 trials, conducted in UK, at 67% [12, 13]. It is, however, much closer to a

regional study conducted in Bangladesh (35.5%) [14] Most of the local adverse effects 121

122 occurred on the first and second post-vaccination day, while a few were recorded on the third

123 day. None were reported in the following days. This is in line with the results of the clinical

124 trials [12].

On the other hand, the systemic adverse effects solicited included headache, fever, flu-like 125

illness, body aches, fatigue and anaphylaxis. At least one systemic effect was reported by 126

42.76% of the study participants, which is considerably lower than the results of the phase 2/127

- 3 trials (86% in the 18–55 years group, 77% in the 56–69 years group, and 65% in the 70 128
- 129 years and older group) [12].

130 Fever, at 30.19%, was present in a greater number of individuals than any other side effect.

131 The phase 2/3 trials show a similar result with 24% incidence in the 18-55 age and no reports

132 of fever in the 55 or above age group. They are also similar to the results of the Bangladeshi

133 study (20%) mentioned above [12, 14]. Another study conducted on those 50 years old and

- 134 above reported a lower incidence of 10% [15].
- 135 Of those that reported fever, nearly three quarters (71.11%) had only a mild case of it.
- Another 23.33% reported moderate fever and very few individuals reported incidence of high 136
- 137 grade fever. This is in accordance with phase 2/3 trials [12].

Body aches were reported by 22.01% of the participants. This figure is much lower than the 138

phase 1/2 trials (60%) and much closer to a regional study (16.4%) [13, 14]. Body aches were 139

140 categorized using a numerical scale from 1 to 10. Over half (62.69%) of the people with body

- 141 aches reported moderate (4 to 6) while a significant number (25.37%) of them also had severe
- 142 body aches (7 to 10). This agrees with prior reports of mostly moderate systemic side-effects.
- 143 [16]
- Headache was present in a mere 4.40% of the respondents. This is, again, in concurrence with 144
- 145 the Bangladeshi study (6.9%) rather than the clinical trial results (68%). Fatigue was reported
- by 3.77% of the participants, a result similar to the Bangladeshi study, and there was not a 146
- single case of flu-like illness [14]. 147
- 148 One case of anaphylactic reaction was also registered, which is in accordance with its rare occurrence in similar studies [12, 16]. This hypersensitivity is probably due to polysorbate 80 149 which is present in adenoviral vector vaccines. These excipients serve to increase absorption, 150 151 improve solubility, and enhance stability of the whole product [17, 18].
- 152 The development and progress of side-effects were assessed through multiple follow-ups
- during the 7-day time period. All of them appeared on Day 1 and most disappeared by Day 4. 153
- 154 A majority of symptoms were present on Day 2 (frequency = 316), followed by Day 1 (219)
- and Day 3 (122). There was always a dramatic fall off, by Day 4 (13). Rarely did a symptom 155
- persist till Day 5 (2). The mean duration of symptoms was (1.9 ± 0.7) , which is very similar to 156
- reported in a study in Bangladesh $(1.9 \pm 1.3 \text{ day})$. 157
- The inferential analysis yielded a significant inverse relationship between age and headache 158
- and age and body aches. Generally, younger individuals were at a greater risk of exhibiting 159
- adverse effects than their older counterparts. This is in accordance with multiple studies [12, 160
- 161 16, 19]. An explanation of this phenomenon lies in the fact that younger individuals form
- stronger immune responses which naturally lead to a greater number of such side-effects [20]. 162
- That may be a reason for the reduced frequencies of side-effects in this study, as the average 163
- 164 age was 51.28 years (AstraZeneca vaccine was available only for those who were 40 years
- old or above, at the time of data collection). Nevertheless, it cannot be the sole cause behind 165 considerable differences in results. This is supported by the fact that some studies have
- 166 167 shown that there are far fewer real-world side-effects of these vaccines [14, 19]. Natural
- 168 variations among different populations also exist and must have a part to play in it.
- No significant associations were found for sex or residence. This is in contrast to past studies 169 170 that found an association between sex and the occurrence of side-effects [17, 19].
- Studies on vaccine side-effects cite past COVID-19 infection and co-morbidities as among 171
- the risk factors for the emergence of post-vaccination adverse effects (although one study 172
- 173 shows an opposite relationship for the latter) [14, 21].

174 Conclusion

- The Oxford-AstraZeneca COVID-19 vaccine side-effects seem to be more prevalent among 175
- younger age groups, which points to increased vaccine safety among older individuals that 176
- are usually more susceptible to severe COVID-19 infection. They are not associated with sex 177
- and residence. However, education is positively associated with them, which might indicate a 178
- 179 nocebo effect among the educated resulting from higher awareness and knowledge about
- side-effects. Finally, we found a substantially reduced number of side-effects, as compared to 180
- 181 the clinical trials, which is an encouraging indicator for vaccine safety.
- We enacted stringent and expansive exclusion criteria to eliminate nearly all chronic illnesses 182
- and co-morbidities that may influence the results. Similarly, we did not include individuals 183
- with past COVID-19 infection (positive PCR test in the past). This was done in the interest of 184
- reducing all possible risk factors, which may inflate the figures, to a minimum and to increase 185
- the confidence in the results generated. While it is a fact that increasing age is inversely 186
- 187 correlated with the development of said side-effects, as mentioned above, the responsibility
- 188 for the considerably lower frequency of their occurrence cannot be laid solely at the feet of
- 189 higher median age, in this study. Further independent, prospective studies are required to
- 190 detect all the factors at play.

191 Acknowledgements

192 None.

193 Limitations

- 194 As the follow-ups were done via phone calls rather than in-person (owing to pandemic-
- induced restrictions), the data is subject to reporting and recall bias. At any rate, 3 equally 195
- spaced follow-ups, which allowed for cross and secondary questioning, kept such issues to a 196
- minimum. No serological testing was included, which may give an idea about the unknown 197
- 198 risk factors.

199 References

207

- 200 1. Khan KS, Mamun MA, Griffiths MD, Ullah I. The mental health impact of the 201 COVID-19 pandemic across different cohorts. International Journal of Mental Health and Addiction. 2020;20(1):380-6. 202
- 2. Szmigiera M. Impact of the coronavirus pandemic on the global economy Statistics 203 204 & Facts [Internet]. Statista. 2021 [cited 2022Jun29]. Available from: 205 https://www.statista.com/topics/6139/covid-19-impact-on-the-globaleconomy/#dossierSummary 206
 - 3. Randolph HE, Barreiro LB. Herd immunity: Understanding covid-19. Immunity. 2020;52(5):737-41.
- 208 4. Zimmer C, Corum J, Wee S-lee, Kristoffersen M. Coronavirus vaccine tracker 209 210 [Internet]. The New York Times. The New York Times; 2020 [cited 2022Jun29]. 211 Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-212 vaccine-tracker.html

213	5.	Craven J. Covid-19 Vaccine tracker [Internet]. Regulatory Affairs Professionals
214		Society (RAPS). [cited 2022Jun29]. Available from: https://www.raps.org/news-and-
215		articles/news-articles/2020/3/covid-19-vaccine-tracker
216	6.	Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. European
217		journal of epidemiology. 2020 Apr;35(4):325-30.
218	7.	Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S, Sela
219		E. Vaccine hesitancy: the next challenge in the fight against COVID-19. European
220		journal of epidemiology. 2020 Aug;35(8):775-9.
221	8.	Luyten J, Bruyneel L, van Hoek AJ. Assessing vaccine hesitancy in the UK
222		population using a generalized vaccine hesitancy survey instrument. Vaccine. 2019
223		Apr 24;37(18):2494-501.
224	9.	Szmyd B, Karuga FF, Bartoszek A, Staniecka K, Siwecka N, Bartoszek A, Błaszczyk
225		M, Radek M. Attitude and behaviors towards SARS-CoV-2 vaccination among
226		healthcare workers: A cross-sectional study from Poland. Vaccines. 2021 Mar
227		4;9(3):218.
228	10.	Ministry of National Health Services Regulations and Coordination. Vaccine
229		Statistics [Internet]. COVID. [cited 2022Jun29]. Available from:
230		https://covid.gov.pk/vaccine-details
231	11.	World Health Organization. Statement for healthcare professionals: How COVID-19
232		vaccines are regulated for safety and effectiveness (revised March 2022) [Internet].
233		World Health Organization. [cited 2022Jun29]. Available from:
234		https://www.who.int/news/item/11-06-2021-statement-for-healthcare-professionals-
235		how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness
236	12.	Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR,
237		Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S. Safety and
238		immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
239		regimen in young and old adults (COV002): a single-blind, randomised, controlled,
240		phase 2/3 trial. The Lancet. 2020 Dec 19;396(10267):1979-93.
241	13.	Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,
242		Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity
243		of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a
244		phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020 Aug
245		15;396(10249):467-78.
246	14.	Khalil M, Mahbub-Uz-Zaman K, Hossain AS, Ahmed F, Chowdhury M, Karim F,
247		Khan ST, Miah M, Alam S, Khaleque N, Kibria M. Adverse events following
248		COVISHIELD vaccination among adult population in Bangladesh. SN
249		Comprehensive Clinical Medicine. 2021 Nov;3(11):2207-13.
250	15.	Iacobucci G. COVID-19: fever, chills, and aches more common when AstraZeneca
251		and Pfizer vaccines are mixed, early data show. BMJ: British Medical Journal
252		(Online). 2021 May 12;373.
253	16.	Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of
254		COVID19 vaccines among Iraqi population; a comparison between the three available
255		vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic
256		Syndrome: Clinical Research & Reviews. 2021 Sep 1;15(5):102207.
257	17.	Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of
258		COVID19 vaccines among Iraqi population; a comparison between the three available
259		vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic
260		Syndrome: Clinical Research & Reviews. 2021 Sep 1;15(5):102207.
261	18.	Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A,
262		Assimakopoulos SF, Gogos C, Kouni SN, Kounis GN, Calogiuri G. Allergic reactions

263		to current available COVID-19 vaccinations: pathophysiology, causality, and
264		therapeutic considerations. Vaccines. 2021 Mar 5;9(3):221.
265	19.	Kadyrova I, Yegorov S, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S,
266		Korshukov I, Baiken Y, Matkarimov B, Miller MS, Hortelano GH, Babenko D.
267		Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective
268		cohort study. medRxiv. 2022 Jan 1.
269	20.	10- Lawton G. You're only as young as your immune system. New Scientist. 2020
270		Mar 28;245(3275):44-8.
271	21.	Riad A, Pokorná A, Mekhemar M, Conrad J, Klugarová J, Koščík M, Klugar M, Attia
272		S. Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU states.
273		Vaccines. 2021 Jun 18;9(6):673.